Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells

Wan,Jing; Shi,Fang; Xu,Zhanzhan; Zhao,Min

doi:10.3892/ijo.2015.3201

Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells

Authors:
- Jing Wan
- Fang Shi
- Zhanzhan Xu
- Min Zhao
View Affiliations

Affiliations: Department of Cardiology, Zhongnan Hospital of Wuhan University, Hubei 430071, P.R. China, Institute of Medical Virology, School of Basic Medical Sciences, Wuhan University, Hubei 430071, P.R. China
Published online on: October 13, 2015 https://doi.org/10.3892/ijo.2015.3201
Pages: 2217-2225

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Eukaryotic initiation factor 4E (eIF4E) plays an important role in cap-dependent translation. The overexpression of eIF4E gene has been found in a variety of human malignancies. In this study, we attempted to identify the potential effects of eIF4E and explore the possibility of eIF4E as a therapeutic target for the treatment of human ovarian cancer. First the activation of eIF4E protein was detected with m7-GTP cap binding assays in ovarian cancer and control cells. Next, the eIF4E-shRNA expression plasmids were used to specifically inhibit eIF4E activity in ovarian cancer cells line A2780 and C200. The effects of knockdown eIF4E gene on cell proliferation, migration and invasion were investigated in vitro. Moreover, the changes of cell cycle and apoptosis of ovarian cancer cells were detected by flow cytometry. Finally, we investigated the effect of knockdown of eIF4E on the chemosensitivity of ovarian cancer cells to cisplatin in vitro. Our results show there is elevated activation of eIF4E in ovarian cancer cells compared with normal human ovarian epithelial cell line. The results of BrdU incorporation and FCM assay indicate that knockdown of eIF4E efficiently suppressed cell growth and induce cell cycle arrest in G1 phase and subsequent apoptosis in ovarian cancer cells. From Transwell assay analysis, knockdown eIF4E significantly decrease cellular migration and invasion of ovarian cancer cells. We also confirmed that knockdown eIF4E could synergistically enhance the cytotoxicity effects of cisplatin to cancer cells and sensitized cisplatin-resistant C200 cells in vitro. This study demonstrates that the activation of eIF4E gene is an essential component of the malignant phenotype in ovarian cancer, and aberration of eIF4E expression is associated with proliferation, migration, invasion and chemosensitivity to cisplatin in ovarian cancer cells. Knockdown eIF4E gene can be used as a potential therapeutic target for the treatment of human ovarian cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Lloyd KL, Cree IA and Savage RS: Prediction of resistance to chemotherapy in ovarian cancer: A systematic review. BMC Cancer. 15:1172015. View Article : Google Scholar : PubMed/NCBI
3	Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI
4	Eckstein N, Servan K, Hildebrandt B, Pölitz A, von Jonquières G, Wolf-Kümmeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, et al: Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 69:2996–3003. 2009. View Article : Google Scholar : PubMed/NCBI
5	Eckstein N: Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res. 30:912011. View Article : Google Scholar : PubMed/NCBI
6	Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE and Boardman CH: Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the Gynecologic Oncology Group. J Clin Oncol. 27:2686–2691. 2009. View Article : Google Scholar : PubMed/NCBI
7	Aletti GD, Dowdy SC, Podratz KC and Cliby WA: Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 197:676.e1–676.e7. 2007. View Article : Google Scholar
8	De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
9	Polunovsky VA and Bitterman PB: The cap-dependent translation apparatus integrates and amplifies cancer pathways. RNA Biol. 3:10–17. 2006. View Article : Google Scholar : PubMed/NCBI
10	Clemens MJ: Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene. 23:3180–3188. 2004. View Article : Google Scholar : PubMed/NCBI
11	Larsson O, Li S, Issaenko OA, Avdulov S, Peterson M, Smith K, Bitterman PB and Polunovsky VA: Eukaryotic translation initiation factor 4E induced progression of primary human mammary epithelial cells along the cancer pathway is associated with targeted translational deregulation of oncogenic drivers and inhibitors. Cancer Res. 67:6814–6824. 2007. View Article : Google Scholar : PubMed/NCBI
12	Dong K, Wang R, Wang X, Lin F, Shen JJ, Gao P and Zhang HZ: Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat. 113:443–456. 2009. View Article : Google Scholar
13	Oridate N, Kim HJ, Xu X and Lotan R: Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther. 4:318–323. 2005. View Article : Google Scholar : PubMed/NCBI
14	De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
15	Culjkovic B, Topisirovic I and Borden KL: Controlling gene expression through RNA regulons: The role of the eukaryotic translation initiation factor eIF4E. Cell Cycle. 6:65–69. 2007. View Article : Google Scholar : PubMed/NCBI
16	Topisirovic I, Siddiqui N, Orolicki S, Skrabanek LA, Tremblay M, Hoang T and Borden KL: Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer. Mol Cell Biol. 29:1152–1162. 2009. View Article : Google Scholar :
17	Ko SY, Guo H, Barengo N and Naora H: Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E. Clin Cancer Res. 15:4336–4347. 2009. View Article : Google Scholar : PubMed/NCBI
18	Graff JR and Zimmer SG: Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 13:272–280. 2012. View Article : Google Scholar : PubMed/NCBI
20	Graff JR, Konicek BW, Carter JH and Marcusson EG: Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68:631–634. 2008. View Article : Google Scholar : PubMed/NCBI
21	Yang SX, Hewitt SM, Steinberg SM, Liewehr DJ and Swain SM: Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. Oncol Rep. 17:281–287. 2007.PubMed/NCBI
22	Liang B, He Q, Zhong L, Wang S, Pan Z, Wang T and Zhao Y: Circulating VEGF as a biomarker for diagnosis of ovarian cancer: A systematic review and a meta-analysis. Onco Targets Ther. 8:1075–1082. 2015.PubMed/NCBI
23	Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT and Sarkar FH: Sensitization of ovarian cancer cells to cisplatin by genistein: The role of NF-kappaB. J Ovarian Res. 1:92008. View Article : Google Scholar : PubMed/NCBI
24	Wan J, Lata C, Santilli A, Green D, Roy S and Santilli S: Supplemental oxygen reverses hypoxia-induced smooth muscle cell proliferation by modulating HIF-alpha and VEGF levels in a rabbit arteriovenous fistula model. Ann Vasc Surg. 28:725–736. 2014. View Article : Google Scholar :
25	Soni A, Akcakanat A, Singh G, Luyimbazi D, Zheng Y, Kim D, Gonzalez-Angulo A and Meric-Bernstam F: eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther. 7:1782–1788. 2008. View Article : Google Scholar : PubMed/NCBI
26	Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman PB, et al: Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell. 5:553–563. 2004. View Article : Google Scholar : PubMed/NCBI
27	Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J and Ramon y Cajal S: Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer. 107:1801–1811. 2006. View Article : Google Scholar : PubMed/NCBI
28	Meric F and Hunt KK: Translation initiation in cancer: A novel target for therapy. Mol Cancer Ther. 1:971–979. 2002.PubMed/NCBI
29	Pinzaglia M, Montaldo C, Polinari D, Simone M, La Teana A, Tripodi M, Mancone C, Londei P and Benelli D: EIF6 over-expression increases the motility and invasiveness of cancer cells by modulating the expression of a critical subset of membrane-bound proteins. BMC Cancer. 15:1312015. View Article : Google Scholar : PubMed/NCBI
30	Rhoads RE: Signal transduction pathways that regulate eukaryotic protein synthesis. J Biol Chem. 274:30337–30340. 1999. View Article : Google Scholar : PubMed/NCBI
31	Brown EJ and Schreiber SL: A signaling pathway to translational control. Cell. 86:517–520. 1996. View Article : Google Scholar : PubMed/NCBI
32	Metzger-Filho O, Moulin C and D'Hondt V: First-line systemic treatment of ovarian cancer: A critical review of available evidence and expectations for future directions. Curr Opin Oncol. 22:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
33	Agarwal R and Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI
34	Wang Y, Han A, Chen E, Singh RK, Chichester CO, Moore RG, Singh AP and Vorsa N: The cranberry flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and cell cycle arrest and increase cisplatin sensitivity in ovarian cancer cells. Int J Oncol. 46:1924–1934. 2015.PubMed/NCBI
35	Meng Q, Xia C, Fang J, Rojanasakul Y and Jiang BH: Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 18:2262–2271. 2006. View Article : Google Scholar : PubMed/NCBI
36	Arafa el-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA and Wani AA: Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 69:8910–8917. 2009. View Article : Google Scholar
37	Johnson SW, Swiggard PA, Handel LM, Brennan JM, Godwin AK, Ozols RF and Hamilton TC: Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res. 54:5911–5916. 1994.PubMed/NCBI
38	Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF and Xia LP: Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 28:1302–1307. 2011. View Article : Google Scholar
39	Bitterman PB and Polunovsky VA: eIF4E-mediated translational control of cancer incidence. Biochim Biophys Acta. 1849:774–780. 2015. View Article : Google Scholar
40	Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, et al: Tumor suppression by small molecule inhibitors of translation initiation. Oncotarget. 3:869–881. 2012. View Article : Google Scholar : PubMed/NCBI
41	Hoeffer CA, Cowansage KK, Arnold EC, Banko JL, Moerke NJ, Rodriguez R, Schmidt EK, Klosi E, Chorev M, Lloyd RE, et al: Inhibition of the interactions between eukaryotic initiation factors 4E and 4G impairs long-term associative memory consolidation but not reconsolidation. Proc Natl Acad Sci USA. 108:3383–3388. 2011. View Article : Google Scholar : PubMed/NCBI